Scientist, Translational Gene Therapy AAV Assays

Pfizer Cambridge , MA 02138

Posted 1 week ago

ROLE SUMMARY

Pfizer's Rare Disease Research Unit (RDRU) focuses on developing drugs for treating rare diseases. The Gene Therapy Translational Research group is part of the RDRU focused on AAV- mediated gene transfer approaches while developing treatments for rare genetically defined diseases that focus on the CNS, neuromuscular, and liver (systemic and metabolic) therapeutic areas. This bench Scientist will be part of a larger interdisciplinary team and contribute to generating various viral vector constructs to advance Pfizer's gene therapy programs. The role requires extensive knowledge and experience in creating synthetic genes, DNA analysis, recombinant protein expression, cloning, quantitative PCR assays, viral potency and quantification assays, fluorescent microscopy, and cell culture techniques. In addition, experience in working on in vivo experiments is desirable. This role also requires contribution to developing and performing cell based and biochemical assays to characterize viral vectors and the encoded transgene products. The bench Scientist will be required to work independently and have a deep knowledge of various molecular biology techniques and assays, in vivo studies, viral vector biology, and strong scientific judgment in making decisions within the area of technical expertise. The role will also involve developing, implementing and running assays in support of different portfolio program.

ROLE RESPONSIBILITIES

  • Design, synthesize, clone and characterize synthetic DNA sequences

  • Perform molecular and cell based assays to characterize AAV gene therapy vectors.

  • Perform biochemical assays to characterize AAV vectors both in vitro and in vivo.

  • Partner with colleagues working on Gene Therapy projects within the rare disease and other organizations.

  • Analyze and present the data to colleagues within and outside of the research unit.

  • Constantly review scientific literature and present novel ideas towards progressing goals

QUALIFICATIONS

  • Ph.D. or Masters Degree in the life sciences with 2+ years of relevant experience or Bachelor's Degree with 5+ years of relevant experience in the field of recombinant AAV vectors.

  • Prior experience with characterization of viral vectors using cell and molecular biology techniques required. Prior experience with rAAV is highly desired, including work with small or large animal models.

  • Evidence of scientific accomplishments in the form of publications and presentations.

  • Evidence of experience working in cross-disciplinary teams.

  • Exceptional communication and presentation skills and demonstrated ability to work effectively as part of a team.

Sunshine Act

Pfizer reports payments and other transfers of value to health care providers as required by federal and state transparency laws and implementing regulations. These laws and regulations require Pfizer to provide government agencies with information such as a health care provider's name, address and the type of payments or other value received, generally for public disclosure. Subject to further legal review and statutory or regulatory clarification, which Pfizer intends to pursue, reimbursement of recruiting expenses for licensed physicians may constitute a reportable transfer of value under the federal transparency law commonly known as the Sunshine Act. Therefore, if you are a licensed physician who incurs recruiting expenses as a result of interviewing with Pfizer that we pay or reimburse, your name, address and the amount of payments made currently will be reported to the government. If you have questions regarding this matter, please do not hesitate to contact your Talent Acquisition representative.

EEO & Employment Eligibility

Pfizer is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status. Pfizer also complies with all applicable national, state and local laws governing nondiscrimination in employment as well as work authorization and employment eligibility verification requirements of the Immigration and Nationality Act and IRCA. Pfizer is an E-Verify employer.

Other Job Details:

  • Last day to Apply: April 8, 2019
  • Eligible for Employee Referral Bonus

N (Other) (United States of America)

Pfizer is an equal opportunity employer and complies with all applicable equal employment opportunity legislation in each jurisdiction in which it operates.


icon no score

See how you match
to the job

Find your dream job anywhere
with the LiveCareer app.
Mobile App Icon
Download the
LiveCareer app and find
your dream job anywhere
App Store Icon Google Play Icon
lc_ad

Boost your job search productivity with our
free Chrome Extension!

lc_apply_tool GET EXTENSION

Similar Jobs

Want to see jobs matched to your resume? Upload One Now! Remove
Vice President Neuroscience Phase I And Gene Therapy Unit Group Leader Clinical Science

Takeda Pharmaceuticals North America

Posted Yesterday

VIEW JOBS 3/19/2019 12:00:00 AM 2019-06-17T00:00 By clicking the "Apply" button, I understand that my employment application process with Takeda will commence and that I agree with Takeda's Privacy Notice, Privacy Policy and Terms of Use. Job Description Are you looking for a patient-focused company that will inspire you and support your career? If so, be empowered to take charge of your future at Takeda. Join us as a Vice President, Neuroscience Phase I and Gene Therapy Unit Group Leader, Clinical Science in our Cambridge office. Here, everyone matters and you will be a vital contributor to our inspiring, bold mission. * The NS Early Development and Gene Therapy Group Leader leads and drives the clinical strategy for all Phase 1 projects across the Neuroscience (NS) portfolio and for NS TAU gene therapy projects taking into consideration the medical, scientific, regulatory and commercial issues for assigned Takeda pipeline compounds. * Leads a multi-disciplinary, multi-regional, matrix teams through highly complex decisions. * This individual has the responsibility for development decisions assessing and integrating the input from various disciplines to create, maintain, and execute Phase 1 development plans that will result in efficient early derisking of pipeline compounds as well as any Phase 1 studies required for regulatory approval of the assigned compound in multiple regions. Applies clinical/medical decision making to clinical development issues. This individual interacts with and influences GPTs and NS TAU senior leadership decision-making for the projects by setting strategic direction. ACCOUNTABILITIES * Clinical participation and leadership * Establishes and leads Global clinical Phase 1 strategy for all Phase 1 projects across the Neuroscience (NS) portfolio and the overall clinical development strategy for NS TAU gene therapy projects * Deliverables include shaping the NS early and gene therapy Development Strategies, Phase 1 and gene therapy Clinical Development Plans and Clinical Protocols. Recommends scope, complexity and size, and influence the budget of all aspects of a program. Provides continual critical evaluation of the development strategy to maintain a state-of-the-art development plan that is competitive and consistent with the latest regulatory requirements, proactive identification of challenges, and development of contingency plans to meet them. * Responsible for high impact global decisions: monitoring and interpreting data from ongoing internal and external studies, assessing the medical and scientific implications, and making recommendations that impact regional and global development such as "go/no go" decisions or modification of development plans or study designs that may have a significant impact on timelines or product labeling. * Synopsis / Protocol Development, Study Execution, & Study Interpretation * Working with GPTs, drives the clinical science activities relating to the preparation / approval of Phase 1 and all phases of gene therapy synopses, protocols and the conduct of clinical studies. Serves as an advisor to other clinical scientists involved in these activities and is accountable for the successful design and interpretation of clinical studies. * Interprets data from an overall scientific standpoint as well as within the context of the medical significance to individual patients. * Trial Medical Monitoring * Responsible for ensuring robust Phase 1 medical monitoring plans, assessing issues related to protocol conduct and/or individual subject safety. Assesses overall safety information for studies and compound in conjunction with Pharmacovigilance. Oversees non-medical clinical scientists with respect to assessment of these issues. * Makes decisions regarding study conduct related to scientific integrity. * External Interactions * Key leader in interactions with regulatory authorities / agencies and clinical development activities undertaken to establish and maintain strong relationships with key opinion leaders relevant to assigned compounds and therapeutic areas. These responsibilities include leadership roles in meetings with the regulatory organizations or key opinion leaders, establishment of strategy for assigned compounds, and the direction of clinical scientists involved in developing documents required to outline the Company positions on research programs or regulatory applications (e.g. briefing reports), materials used for meeting presentations, and formal responses to communications received from the regulatory organizations or opinion leaders. Lead roles will also be taken on the incorporation of advice / recommendations received into the design of clinical studies / programs as appropriate; accountable for the successful completion of related objectives. * Due Diligence, Business Development and Alliance Projects Contributes to the identification and evaluation of potential business development opportunities, conduct due diligence evaluations, and development and negotiation of clinical development plans for potential alliances and or in-licensing opportunities. Assesses scientific, medical, and development feasibility, evaluating strategic fit with overall portfolio, evaluating complete or ongoing clinical trials, assessing regulatory interactions and future development plans * interacting with upper management of potential partner/acquisition companies during DD visits and alliance negotiations, and representing clinical science on internal assessment teams. * May serve as clinical contact point for ongoing alliance projects and interface with partner to achieve Takeda's strategic goals while striving to maintain good working relationship between Takeda and partner. * Leadership, Task Force Participation, Upper Management Accountability * Member of TAU leadership team and contributes to NS TAU strategy. May represent clinical science on multidisciplinary task forces across divisions. Lead global cross-functional teams, as appropriate. * Hires, manages, mentors, motivates, empowers, develops and retains staff to support assigned activities. Conducts performance reviews and drive goal setting and development planning. CORE ELEMENTS RELATED TO THIS ROLE * The NS Phase I and Gene Therapy Unit Group Leader provides overall leadership to the Phase 1 plans and studies across the portfolio, in particular ensuring the technical excellence and subject safety in first-in-human trials. This role includes the full scope of people management tasks. The NS Phase I and Gene Therapy Unit Group Leader contributes to portfolio-level strategy. He/she is responsible for planning and executing towards future departmental needs. The NS Phase I and Gene Therapy Unit Group Leader works fully autonomously, contributes to designing new cross-functional processes, is frequently involved in evaluation of Business Development opportunities and works well and may lead interactions with external partners. He/she is expected to contribute the overall performance of Takeda R&D. EDUCATION, BEHAVIOURAL COMPETENCIES AND SKILLS: * MD or internationally recognized equivalent plus 10 years of clinical pharmacology and early phase NS research experience within the pharmaceutical industry, CRO health-related consulting company, or biomedical/clinical experience within academia (or a combination of afore mentioned). * Previous experience successfully leading clinical development team/matrix teams with responsibility for studies in multiple regions. * Deep IND/CTA experience and NDA/MAA/Submission experience preferred. * Management experience Skills * Superior communication, strategic, interpersonal and negotiating skills * Ability to proactively predict issues and solve problems * Ability to drive decision-making within a multi-disciplinary, multi-regional, matrix teams * Diplomacy and positive influencing abilities Knowledge * Therapeutic area knowledge relevant to mechanism of action * Regional/global Regulatory requirements * GCP/ICH * Emerging research in designated therapeutic area TRAVEL REQUIREMENTS: * Ability to drive to or fly to various meetings or client sites, including overnight trips. Some international travel may be required. * Requires approximately 15 - 25% travel. WHAT TAKEDA CAN OFFER YOU: * 401(k) with company match and Annual Retirement Contribution Plan * Tuition reimbursement * Company match of charitable contributions * Health & Wellness programs including onsite flu shots and health screenings * Generous time off for vacation and the option to purchase additional vacation days * Community Outreach Programs Empowering Our People to Shine Takeda is an EEO employer of minorities, women, disabled, protected veterans, and considers qualified applicants with criminal histories in accordance with applicable laws. For more information, visit http://www.takeda.us/careers/EEO_Policy_Statement.aspx Learn more at takedajobs.com. No Phone Calls or Recruiters Please. * LI-CS1 Locations Cambridge, MA Worker Type Employee Worker Sub-Type Regular Time Type Full time Takeda Pharmaceuticals North America Cambridge MA

Scientist, Translational Gene Therapy AAV Assays

Pfizer